S-1: Estrella Immunopharma Files S-1 for Resale of 2.5M Shares

Estrella Immunopharma, a clinical-stage biopharmaceutical company, filed an S-1 registration statement for the resale of up to 2,541,206 shares of common stock by selling stockholders, while reporting continued operating losses and a going concern doubt.

Summary

• Estrella Immunopharma is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for cancers and autoimmune diseases, leveraging its ARTEMIS T-Cell Receptor Platform.
• The company's lead product candidate, EB103, is a CD19-directed ARTEMIS T-cell therapy for relapsed or refractory B-cell malignancies, currently in a Phase I/II clinical trial (STARLIGHT-1).
• As of September 30, 2025, nine patients have been treated in the STARLIGHT-1 trial, with the high-dose cohort achieving a 100% complete response rate at Month 1 in all evaluable patients in the Phase I dose-escalation phase, with no treatment-related serious adverse events reported.
• The company is also developing EB104, a dual-targeting T-cell therapy for CD19 and CD22, and exploring a 'mark and kill' strategy for solid tumors with Imugene's CF33-CD19t oncolytic virus.
• Estrella Immunopharma reported net losses of approximately $4.8 million for the three months ended September 30, 2025, and $12.5 million for the nine months ended September 30, 2025.
• As of September 30, 2025, the company had an accumulated deficit of approximately $36.4 million and cash and cash equivalents of approximately $1.6 million.
• The company's independent registered public accounting firm has included an explanatory paragraph in its report expressing substantial doubt about the company's ability to continue as a going concern.
• The S-1 registration statement is for the resale of up to 2,541,206 shares of Common Stock by selling stockholders, including shares from private placements and contingent true-up provisions, representing approximately 6.7% of total outstanding shares as of December 1, 2025.
• The company has a Common Stock Purchase Agreement with White Lion Capital LLC, allowing it to sell up to $50 million in newly issued shares, with approximately $79,491 raised for 70,000 shares as of September 30, 2025.
• Estrella Immunopharma is substantially dependent on its parent company, Eureka Therapeutics, Inc., for intellectual property licensing, clinical trial services, and manufacturing of product candidates.

Sentiment

Score: 3

Explanation: The sentiment is low due to significant and increasing operating losses, a substantial accumulated deficit, and the explicit 'going concern' warning from auditors. While there is positive early clinical data for EB103, the financial instability and heavy reliance on future capital raises, coupled with potential dilution and related-party risks, outweigh the clinical progress from an investment perspective.

Positives

• EB103's Phase I dose-escalation phase in the STARLIGHT-1 clinical trial showed a favorable safety profile with no treatment-related serious adverse events.
• The high-dose cohort in the EB103 Phase I trial achieved a 100% complete response rate at Month 1 in all evaluable patients, including high-risk individuals ineligible for other CD19 products.
• An independent Data Safety Monitoring Board (DSMB) recommended advancing the STARLIGHT-1 trial into the Phase II expansion phase at the recommended Phase II dose.
• The company has an exclusive license from Eureka Therapeutics, Inc. for ARTEMIS technology in CD19 and CD22-targeted T-cell therapies.
• Collaboration with Imugene to explore EB103's use with CF33-CD19t oncolytic virus offers a potential 'mark and kill' strategy for solid tumors, addressing a major barrier in T-cell therapy.

Negatives

• The company has a history of significant operating losses, with net losses of $4.8 million for Q3 2025 and $12.5 million for the nine months ended September 30, 2025.
• An accumulated deficit of approximately $36.4 million as of September 30, 2025, indicates a lack of sustained profitability since inception.
• The company's ability to continue as a going concern is in substantial doubt, requiring significant additional funding to finance operations.
• Cash and cash equivalents were approximately $1.6 million as of September 30, 2025, and a working capital deficit of approximately $11.3 million, highlighting liquidity challenges.
• The sale of up to 2,541,206 shares by selling stockholders, including those with price-protection provisions, could create market overhang and downward pressure on the stock price.
• Management has limited experience in managing day-to-day operations of a public company, potentially leading to increased costs and compliance challenges.
• The CEO, Dr. Cheng Liu, also serves as CEO and President of Eureka Therapeutics, Inc., raising potential conflicts of interest and limiting his full-time dedication to Estrella.

Risks

• Significant operating losses are expected to continue for the foreseeable future, and profitability may never be achieved or maintained.
• Substantial additional funding is required to advance product candidates, and there is no guarantee that such funding will be available on acceptable terms or at all.
• Product candidates are in early clinical development, and clinical trials are lengthy, expensive, and have uncertain outcomes, with no guarantee of successful completion or demonstration of clinical benefit.
• Heavy dependence on Eureka Therapeutics, Inc. for intellectual property, clinical trial conduct, and manufacturing of product candidates, with risks of unsatisfactory performance or disruption of the relationship.
• Inability to obtain and maintain intellectual property protection for technology and products could harm commercialization efforts.
• Failure to obtain U.S. or foreign regulatory approval would prevent commercialization of product candidates.
• Intense competition from larger, better-funded pharmaceutical and biotechnology companies developing T-cell therapies and other novel treatments.
• Difficulties in managing growth and expanding operations, including recruiting and retaining qualified personnel.
• Significant risk of product liability claims, with potential for substantial costs and adverse effects on business.
• Exposure to fraud or misconduct by employees, principal investigators, consultants, and commercial collaborators.
• Dependence on sophisticated information technology systems and data processing, with risks of security or data privacy breaches.
• Non-compliance with environmental, health, and human safety laws and regulations could adversely affect the business.
• Potential adverse effects on financial position and operations due to military actions in Ukraine and the war between Israel and Hamas, and related economic sanctions.
• Volatility in capital markets and lower market prices for securities may affect the ability to access new capital.
• Inflation and higher interest rates could increase operating costs and affect liquidity and capital raising ability.
• Potential for delisting from Nasdaq if compliance with listing standards is not maintained, leading to reduced trading price and liquidity.
• Risk of class action litigation due to expected stock volatility.
• As a controlled company, Estrella may rely on exemptions from certain corporate governance requirements, potentially reducing protections for other shareholders.
• Future sales and issuances of Common Stock or rights to purchase Common Stock could result in additional dilution for existing stockholders.
• Material weaknesses in internal control over financial reporting could affect the reliability of financial statements.
• Intellectual property rights may not cover products or processes, or may be invalid/unenforceable, and third parties may allege infringement.
• Patent terms may not adequately protect the competitive position for a sufficient period.
• Changes in U.S. patent law or foreign patent law could diminish the value of patents.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• Potential claims of wrongful use or disclosure of third-party trade secrets by employees or consultants.
• Risk of inventorship disputes for in-licensed patents and other intellectual property.
• Non-compliance with government patent agency requirements could reduce or eliminate patent protection.
• If trademarks and trade names are not adequately protected, name recognition and business may be adversely affected.
• Negative data from licensed technology in other territories (e.g., JW Territory) could negatively affect development in the Licensed Territory.
• Ongoing regulatory obligations and continued regulatory review, even if product candidates are approved, may result in significant additional expense and potential market withdrawal.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies could harm the business.
• Non-compliance with U.S. and foreign anti-corruption and anti-money laundering laws can subject the company to criminal or civil liability.
• Disruptions at the FDA and other government agencies due to staffing reductions or shutdowns could hinder regulatory review.
• Natural disasters or other unplanned events could adversely affect business continuity and operations.

Future Outlook

The company expects its expenses and operating losses to increase significantly as it continues to advance product candidates through clinical development. Future capital requirements are substantial and uncertain, depending on the timing and progress of preclinical and clinical development, regulatory approvals, manufacturing, and commercialization efforts. The company plans to raise additional capital but cannot guarantee its availability on acceptable terms. The ability to achieve or sustain profitability is dependent on successfully developing and commercializing product candidates and obtaining regulatory approvals.

Management Comments

• Management believes that existing cash and cash equivalents, combined with the ability to raise funds through the Equity Line Shares to White Lion, will be sufficient to fund operations for at least the next 12 months from the filing date.
• Dr. Cheng Liu, CEO and President, is expected to fulfill his duties but is not required to provide a specific number of hours to the business per week or month, due to his dual role as Founder, President, and CEO of Eureka Therapeutics, Inc.

Industry Context

Estrella Immunopharma operates in the highly competitive and capital-intensive clinical-stage biopharmaceutical industry, specifically focusing on T-cell therapies. The company aims to overcome limitations of traditional CAR-T therapies, such as high toxicity and prohibitive costs, to make T-cell treatments more accessible. Its 'mark and kill' strategy for solid tumors, in collaboration with Imugene, addresses a significant unmet need in oncology, as T-cell therapies have had limited success in this area to date. The industry is characterized by lengthy and expensive development processes, rigorous regulatory requirements, and intense competition from larger, well-funded companies.

Corporate Governance

Legal Proceedings

• The company is or may be party to certain legal proceedings, as well as certain asserted and un-asserted claims, but amounts accrued and reasonably possible losses are not deemed material to the unaudited condensed consolidated financial statements.
• Third parties may assert infringement claims against the company, its licensors, or strategic collaborators based on existing or future patents, which could lead to costly litigation and divert management attention.

Related Party Transactions

• **License Agreement with Eureka Therapeutics, Inc. and Eureka Therapeutics (Cayman) Ltd. (June 28, 2022):** Grants Estrella an exclusive license for ARTEMIS technology in CD19 and CD22-targeted T-cell therapies. Eureka is responsible for manufacturing and supplying clinical quantities of licensed products. Estrella paid a $1.0 million upfront fee and made milestone payments of $50,000 for IND submission (Oct 10, 2023) and $50,000 for the first patient dosed (Sep 3, 2024). Future development, regulatory, and commercial milestone payments and single-digit royalty payments on net sales are required.
• **Services Agreement with Eureka Therapeutics, Inc. (June 28, 2022):** Eureka provides technology transfer and technical assistance services. Estrella paid $10.0 million in installments and reimburses pass-through costs. As of Sep 30, 2025, all amounts owed under this agreement were settled.
• **Statement of Work No. 001 with Eureka Therapeutics, Inc. (March 4, 2024):** For clinical trial services related to the Phase I/II STARLIGHT-1 trial of EB103. Total milestone-based payments of up to $33.0 million (excluding pass-through costs) are outlined, assuming 20 patients and one clinical site. An additional $500,000 is payable for a second site activation. As of Sep 30, 2025, Estrella paid $3.5 million for milestones and deposited $1.5 million for patient treatment expenses. Accrued liabilities to related parties for dosing and site activation milestones totaled approximately $12.9 million as of Sep 30, 2025.
• **Amendment No. 1 to SOW No. 001 (May 13, 2024):** Clarifies that if Estrella terminates or suspends the engagement, it is only obligated to compensate Eureka for services provided, pass-through costs incurred, and non-cancellable third-party commitments prior to termination notice.
• **Consulting Agreement with CoFame Investment Holding LLC (November 1, 2024):** CoFame, managed by board chairperson Hong Zhang, provides advisory and consulting services for activities in Asia. Accrued consulting fees were $18,333 as of Sep 30, 2025, and $36,667 as of Dec 31, 2024. Consulting expense was $54,999 for Q3 2025 and $164,996 for 9M 2025.
• **Series AA Preferred Stock (June 28, 2022):** Eureka contributed assets to Estrella in exchange for 105,000,000 shares of Estrella's Series AA Preferred Stock. As of Sep 30, 2025, Eureka owned approximately 66.0% of the company on a fully diluted basis.
• **Office Sublease Agreements with Eureka Therapeutics, Inc. (various dates):** Estrella leases office space from Eureka for $2,000 per month. Agreements were renewed, with the latest expiring December 31, 2025. Rent expense was $6,000 for Q3 2025 and $18,000 for 9M 2025. Outstanding lease payments of $4,000 were recorded as accounts payable to a related party as of Sep 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity offerings and the resale of shares by selling stockholders. The 'going concern' doubt and recurring losses pose substantial risk to investment value. Price-protection provisions for some selling stockholders may incentivize sales at lower prices, potentially depressing the stock.
• **Employees:** The company's ability to continue as a going concern and raise capital directly impacts job security and the long-term viability of employment. Stock-based compensation is a significant part of executive pay, linking their interests to company performance.
• **Customers (future patients):** The successful development and commercialization of T-cell therapies like EB103 and EB104 could offer new treatment options for patients with B-cell malignancies and potentially solid tumors, addressing unmet medical needs.
• **Suppliers/Creditors:** Eureka Therapeutics, Inc. is a major related-party supplier and creditor, with significant accrued liabilities and ongoing contractual obligations. The company's financial health directly impacts its ability to meet these obligations.
• **Regulatory Authorities:** The company's operations are subject to extensive governmental regulations, and compliance failures could lead to penalties and impact product development and commercialization.

Next Steps

• Continue the ongoing Phase I/II STARLIGHT-1 clinical trial for EB103, advancing into the Phase II expansion phase.
• Continue the development of preclinical programs for other product candidates.
• Seek regulatory approval for EB103 and any future product candidates.
• Expand operational, financial, and management systems and increase personnel to support development and commercialization efforts.
• Continue to develop, perfect, and defend the intellectual property portfolio.
• Raise substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, grants, and other marketing and distribution arrangements.
• Evaluate and potentially enter into additional strategic transactions, such as collaborations and geographic partnerships.

Key Dates

Recommendation

Estrella Immunopharma presents a high-risk, high-reward profile. While the early Phase I clinical trial results for EB103 are promising, showing a 100% complete response rate in the high-dose cohort with no serious adverse events, the company faces severe financial challenges, including recurring significant operating losses and an explicit 'going concern' warning from its auditors. The need for substantial future capital raises, potential dilution from existing and future equity offerings, and heavy reliance on its controlling shareholder, Eureka Therapeutics, for critical operations and intellectual property, introduce considerable uncertainty. The stock price volatility and the potential for market overhang from selling stockholders further complicate the investment landscape. A 'hold' recommendation acknowledges the positive clinical developments and long-term potential of its T-cell therapy platform but emphasizes the significant financial and operational risks that currently make a 'buy' recommendation premature for a seasoned investor or institution.

Keywords

T-cell therapies, Biopharmaceutical, Oncology, Autoimmune diseases, ARTEMIS platform, EB103, CD19-directed therapy, STARLIGHT-1 clinical trial, B-cell Non-Hodgkin's Lymphoma, EB104, CD19/CD22 dual-targeting, Solid tumors, Oncolytic virus, CF33-CD19t, Eureka Therapeutics, Imugene, Clinical-stage, SEC filing, S-1 registration, Equity financing, Going concern, Intellectual property, Nasdaq Capital Market, ESLA